Navigation Links
Human stem cells predict efficacy of Alzheimer drugs
Date:12/6/2013

Why do certain Alzheimer medications work in animal models but not in clinical trials in humans? A research team from the University of Bonn and the biomedical enterprise LIFE & BRAIN GmbH has been able to show that results of established test methods with animal models and cell lines used up until now can hardly be translated to the processes in the human brain. Drug testing should therefore be conducted with human nerve cells, conclude the scientists. The results are published by Cell Press in the journal "Stem Cell Reports".

In the brains of Alzheimer patients, deposits form that consist essentially of beta-amyloid and are harmful to nerve cells. Scientists are therefore searching for pharmaceutical compounds that prevent the formation of these dangerous aggregates. In animal models, certain non-steroidal anti-inflammatory drugs (NSAIDs) were found to a reduced formation of harmful beta-amyloid variants. Yet, in subsequent clinical studies, these NSAIDs failed to elicit any beneficial effects.

"The reasons for these negative results have remained unclear for a long time", says Prof. Dr. Oliver Brstle, Director of the Institute for Reconstructive Neurobiology of the University of Bonn and CEO of LIFE & BRAIN GmbH. "Remarkably, these compounds were never tested directly on the actual target cells the human neuron", adds lead author Dr. Jerome Mertens of Prof. Brstle's team, who now works at the Laboratory of Genetics in La Jolla (USA). This is because, so far, living human neurons have been extremely difficult to obtain. However, with the recent advances in stem cell research it has become possible to derive limitless numbers of brain cells from a small skin biopsy or other adult cell types.

Scientists transform skin cells into nerve cells

Now a research team from the Institute for Reconstructive Neurobiology and the Department of Neurology of the Bonn University Medical Center together with colleagues from the LIFE & BRAIN GmbH and the University of Leuven (Belgium) has obtained such nerve cells from humans. The researchers used skin cells from two patients with a familial form of Alzheimer's Disease to produce so-called induced pluripotent stem cells (iPS cells), by reprogramming the body's cells into a quasi-embryonic stage. They then transformed the resulting so-called "jack-of-all-trades cells" into nerve cells.

Using these human neurons, the scientists tested several compounds in the group of non-steroidal anti-inflammatory drugs. As control, the researchers used nerve cells they had obtained from iPS cells of donors who did not have the disease. Both in the nerve cells obtained from the Alzheimer patients and in the control cells, the NSAIDs that had previously tested positive in the animal models and cell lines typically used for drug screening had practically no effect: The values for the harmful beta-amyloid variants that form the feared aggregates in the brain remained unaffected when the cells were treated with clinically relevant dosages of these compounds.

Metabolic processes in animal models differ from humans

"In order to predict the efficacy of Alzheimer drugs, such tests have to be performed directly on the affected human nerve cells", concludes Prof. Brstle's colleague Dr. Philipp Koch, who led the study. Why do NSAIDs decrease the risk of aggregate formation in animal experiments and cell lines but not in human neurons? The scientists explain this with differences in metabolic processes between these different cell types. "The results are simply not transferable", says Dr. Koch.

The scientists now hope that in the future, testing of potential drugs for the treatment of Alzheimer's disease will be increasingly conducted using neurons obtained from iPS cells of patients. "The development of a single drug takes an average of ten years", says Prof. Brstle. "By using patient-specific nerve cells as a test system, investments by pharmaceutical companies and the tedious search for urgently needed Alzheimer medications could be greatly streamlined".


'/>"/>

Contact: Dr. Oliver Brüstle
r.neuro@uni-bonn.de
49-228-688-5500
University of Bonn
Source:Eurekalert  

Related medicine news :

1. New drug prevents spread of human prostate cancer cells
2. Scientists solving the mystery of human consciousness
3. First targeted nanomedicine to enter human clinical studies
4. Edith Mitchell, M.D., FACP, named 2012 recipient of ASCO Humanitarian Award
5. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
6. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
7. IBN discovers human neural stem cells with tumor targeting ability
8. RANK protein promotes the initiation, progression and metastasis of human breast cancer
9. CNIO researchers describe new functions of cohesin relevant for human disease
10. New Clues to the Evolution of the Human Brain
11. Humanist funerals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Human stem cells predict efficacy of Alzheimer drugs
(Date:6/24/2017)... ... June 24, 2017 , ... The weather is heating up and the ... business owners should be aware that the summer months provide more than warmer temperatures ... and keys can be negatively affected from direct exposure to the sun. When it ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island ... Care Management Alerts and Dashboards, an innovative new service enabling healthcare providers to ... Care Management Alerts and Dashboards provide near real-time data about patients admitted to ...
(Date:6/23/2017)... ... June 23, 2017 , ... By scoring 100% for ... consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's work as ... of all charities reviewed by Charity Navigator and earns ANRF a spot on their ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet ... , But how often do ophthalmologists and optometrists in Sweden recommend the use of ... with early symptoms of AMD? A study published recently in Dove Medical ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... in Newburgh, New York, has recently begun offering three new minimally invasive procedures ... best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited to bring microneedling, ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... Israel , May 30, 2017 DarioHealth Corp. (NASDAQ: ... big data solutions, today announced that it will be presenting at ... at 8:00 AM PT. Erez Raphael , CEO, of DarioHealth ... The conference will be held on June 6th & 7th, 2017 ... companies in the small / micro-cap space. ...
(Date:5/30/2017)... Therapix Biosciences Ltd. (Nasdaq: TRPX), a ... development of cannabinoid-based drugs, today announced that the ... three upcoming scientific and investor conferences in June: ... ... Wednesday, June 7 ...
(Date:5/26/2017)... , May 26, 2017  Endo International plc (NASDAQ: ... President and CEO, will represent the Company in a fireside ... Conference on Tuesday, June 13, 2017 at 10:40 a.m. PT ... Terranea Resort in Rancho Palos Verdes, CA. ... the event will be available on the Company,s website at ...
Breaking Medicine Technology: